Comparative Analysis of Holmium Laser Enucleation of the Prostate (HoLEP) and Robotic Assisted Simple Prostatectomy (RASP) in BPH Management: A Systematic Review and Meta-Analysis.

PURPOSE As the prevalence of Benign Prostatic Hyperplasia (BPH) increases, the demand for surgical interventions that optimize patient outcomes while minimizing complications grows. This systematic review compares the efficacy, efficiency, and safety of Holmium Laser Enucleation of the Prostate (HoLEP) with Robotic-Assisted Simple Prostatectomy (RASP), providing insights for evidence-based surgical decision-making in BPH treatment. MATERIALS AND METHODS Adhering to PRISMA guidelines, the study protocol was registered with Prospero [CRD42024509627]. Searches were conducted in Medline, Embase, Web of Science, Scopus, and CINAHL up to February 1, 2024, to include studies that compare HoLEP and RASP in BPH patients. Risk of Bias was evaluated using the Newcastle Ottawa Scale. RESULTS HoLEP and RASP demonstrated equivalent effectiveness in treating BPH, as shown by similar functional outcomes like maximum urinary flow rate and post-void residual volume. However, HoLEP outperformed RASP in several operational efficiency metrics, reducing operative time by 49.48 minutes, hospitalization duration by 1.5 days, and catheterization period by 3.8 days. HoLEP also significantly reduced the risk of blood transfusions by 75%. Patients undergoing RASP were 1.87 times more at risk for grade 2 complications and 3.41 times more at risk for developing grade 3 or above complications. CONCLUSIONS HoLEP and RASP are effective for managing BPH. HoLEP shows advantages in recovery metrics and lower blood transfusion rates, while RASP benefits from ease of implementation in robotic-equipped facilities. Optimizing surgical outcomes will depend on reducing disparities in technique adoption, improving surgical training, and aligning with evidence-based guidelines.